Docetaxel in Head and Neck Cancer

• Status: Completed
• Trial end date: 2010-07-01

Summary

Primary Objective:

• Phase II: To determine the best treatment scheme (TPF vs. PF).

• Phase III: To compare the time to progression and the treatment failure at the 3 arms.

Secondary objectives:

• To evaluate the safety at the 3 arms.

• To compare the progression , overall survival and locoregional control at the 3 arms.

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Sanofi
• Treatments: Cisplatin; Docetaxel; Fluorouracil